股价表现 - Elevance Health股价在过去一年下跌27% [1] - 公司股票在过去1年、3年和5年期间显著跑输大盘（SPY） [1]

BENSALEM, Pa., May 28, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ELEVANCE HEALTH, INC. (ELV), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 11, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices o ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Elevance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Elevance between April 18, 2024 and October 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

估值分析 - 公司当前12个月前瞻市盈率仅为10.35倍 显著低于五年中位数13.46倍和行业平均13.86倍 [1] - 相比同业公司UnitedHealth(12.06倍)和Humana(14.73倍) 估值更具吸引力 [1] - 获得Zacks价值评分A级 凸显估值基本面优势 [1] 业务增长驱动 - 商业保险业务稳健增长 2024年风险型和费用型会员数同比分别增长4.6%和1% [4] - 个人商业保险业务表现突出 2025年一季度单季增长14.2% [4] - 政府业务通过退出低效市场实现优化 在渗透不足州份的Medicare Advantage业务存在扩张空间 [5] - 牙科和视力保险会员保持增长势头 [5] 财务指标 - 投资资本回报率达9.94% 远超行业平均5.79% [6] - 市值841亿美元 具备规模优势推动高毛利业务并购 [6] - 2025年一季度回购8.8亿美元股票 剩余授权回购额度84亿美元 [7] - 股息收益率1.82% 高于行业平均1.40% [7] 市场表现 - 年内股价上涨1.9% 跑赢行业指数和标普500指数 [8] - 同业公司UnitedHealth和Humana同期股价下跌 [8] 盈利预测 - 2025年和2026年EPS共识预期同比增幅分别为4.2%和13.8% [11] - 同期营收预期增幅为11.2%和7.1% [11] - 过去四个季度中有三次盈利超预期 [11] 业务挑战 - Medicaid和Medicare Supplement会员数量下降导致总收入减少 [12] - 医疗福利支出比率从2023年87%升至2024年88.5% 预计2025年达88.7% [13] - 药品福利管理业务面临特朗普政府"最惠国"药价政策不确定性 [14]

诉讼背景 - 针对Elevance Health Inc的证券集体诉讼已提交 代表在2024年4月18日至10月16日期间购买公司证券的投资者 [1] - 投资者需在2025年7月11日前申请成为首席原告代表 [2] 公司业务 - Elevance总部位于印第安纳波利斯 是一家提供健康保险计划的医疗保健公司 包括与各州签订合同为符合资格的受益人管理Medicaid福利 [3] - 各州定期进行资格重新确定审查 以评估Medicaid受益人是否仍符合覆盖条件 [3] 指控内容 - 公司向投资者表示密切监控与"重新确定"流程相关的成本趋势 并保证与各州协商的保费费率足以应对成本状况 [4] - 实际上 被移出Medicaid计划的成员平均比仍符合资格者更健康 导致剩余成员医疗利用率显著上升 这一变化未充分反映在公司费率协商或2024年财务指引中 [5] 市场反应 - 2024年7月17日公司披露"预计下半年Medicaid利用率将上升" 导致股价下跌32.21美元(5.8%)至520.93美元 [6] - 2024年10月17日公布Q3财报显示每股收益低于预期1.33美元(13.7%) 主因Medicaid业务医疗成本上升 同时将2024年EPS指引从37.20美元下调至33.00美元(降幅11.3%) [7] - 上述披露导致股价再跌52.61美元(10.6%)至444.35美元 [8]

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of Elevance Health, Inc. (NYSE: ELV) common stock between April 18, 2024 and October 16, 2024. Elevance is a healthcare company that, among other things, provides health insurance plans to a variety of markets. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations t ...

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed to ...

NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed to ...

行业概述 - 联合健康集团(UNH)和Elevance健康(ELV)是美国医疗保健计划领域的两大巨头，拥有强大声誉、多元化业务和稳健财务记录 [1] - 行业近期面临成本上升和报销不确定性的压力，但长期需求前景乐观，尤其是管理式医疗服务 [2] 联合健康集团(UNH)分析 - 公司通过Optum部门在保险和健康服务领域具有无与伦比的规模优势，历史业绩稳定且资本配置审慎 [3] - 近期市值从5667亿美元暴跌至2691亿美元，主要因保费不及预期、医疗成本上升导致季报业绩未达标，并撤回2025年财务指引 [4] - 管理层变动(CEO更替)和涉嫌医疗保险欺诈的刑事调查加剧了投资者担忧 [5] - 业务多元化覆盖商业保险/联邦医疗保险/医疗补助，自由现金流稳定，股息率2.83%高于同行 [6] Elevance健康(ELV)分析 - 公司规模较小但运营势头强劲，重点发展政府支持的医疗补助和联邦医疗保险优势计划 [7] - 最新季报超预期，保费收入同比增长14.5%至409亿美元，运营费用率改善70个基点至10.9% [8][9] - 长期债务资本比39.7%低于UNH的42.7%，财务结构更稳健 [10] 财务与估值比较 - Zacks预估显示ELV 2025年EPS预计增长4.2%，营收增11.2%；UNH营收预计增12.9%但EPS将下降15.5% [11] - ELV远期市盈率10.60倍低于UNH的11.76倍，估值更具吸引力 [12] - 年内股价表现：ELV上涨4.2%，UNH暴跌41.4% [14] 综合结论 - UNH虽具规模优势但面临短期成本压力，ELV展现出更强的执行力和成本控制能力 [16] - 基于更优估值、盈利预期上调及股价表现，ELV当前更具投资吸引力 [17]

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed to ...